EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY 4.0

Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA Vaccine

Spyros Chalkias iD, Antionette Pragalos, Adebayo Akinsola, Gary Berman, Madhavi Ampajwala, Jay Meyer, Lorraine Schoch, Wen Zhou, Yamuna D Paila, Weiping Deng, Jing Feng, Elizabeth de Windt und 3 weitere

The Journal of Infectious Diseases · 15.04.2025 · 231 (4) · e754-e763

DOI: 10.1093/infdis/jiaf022 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 10.01.2025. Verfasst von Spyros Chalkias und 14 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Development, Infectious Diseases, Moderna, Inc, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Spike Glycoprotein, Coronavirus, COVID-19 Vaccines, SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Moderna, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background mRNA-1283 is an investigational coronavirus disease 2019 (COVID-19) mRNA vaccine encoding the receptor-binding and N-terminal domains of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein in contrast to the original mRNA-1273 vaccine, which encodes the full-length spike protein.

Methods

A phase 2a, dose-ranging, observer-blind, randomized study conducted in adults (aged ≥18 years) previously vaccinated with mRNA-1273 evaluated the safety and immunogenicity of a single dose of mRNA-1283 (2.5, 5, and 10 µg) and its bivalent formulation, mRNA-1283.211 (5 and 10 µg; encoding original SARS-CoV-2 and Beta) against the comparator mRNA-1273 vaccine, 50 µg (part A). A subsequent, open-label study (part B) evaluated the safety and immunogenicity of a monovalent Omicron BA.1 vaccine, mRNA-1283.529 (5 and 10 µg).

Results

A total of 340 participants were randomized in part A, and 200 participants were enrolled in part B. All dose levels of mRNA-1283 vaccines were well tolerated and increased the neutralizing antibody (nAb) responses at day 29 compared to baseline against SARS-CoV-2 D614G and Beta. The nAb responses elicited by mRNA-1283 were higher than those elicited by mRNA-1273. mRNA-1283.529 (part B) increased nAb at day 29 against Omicron BA.1. Antibody responses remained detectable for a year postvaccination. Conclusions mRNA-1283 was well tolerated and exhibited improved immunogenicity compared to mRNA-1273. Clinical Trials Registration NCT05137236.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spike Glycoprotein, CoronavirusCOVID-19 VaccinesSARS-CoV-2COVID-19Immunogenicity, VaccineHumansFemaleAdultMaleMiddle AgedAntibodies, ViralAntibodies, NeutralizingVaccines, Synthetic2019-nCoV Vaccine mRNA-1273Young AdultAgedmRNA VaccinesAdolescentSingle-Blind Method

Stichwörter der Autor:innen

COVID-19SARS-CoV-2booster vaccinationclinical studymRNA vaccinesmRNA-1273mRNA-1283

Substanzen

Spike Glycoprotein, CoronavirusCOVID-19 Vaccinesspike protein, SARS-CoV-2Antibodies, ViralAntibodies, NeutralizingVaccines, Synthetic2019-nCoV Vaccine mRNA-1273mRNA Vaccines

Autor:innen und Institutionen

  • Clinical Development, Infectious Diseases, Moderna, Inc, Cambridge, Massachusetts, USA.
  • CTI Clinical Trial and Consulting Services, Covington, Kentucky, USA.
  • Tekton Research, Atlanta, Georgia, USA.
  • Clinical Research Institute, Inc, Minneapolis, Minnesota, USA.
  • Advanced Care Research Centers (ACRC) Trials, Plano, Texas, USA.
  • Velocity Clinical Research, Lincoln, Nebraska, USA.

ORCID-Profile: Spyros Chalkias

Förderung

  • Moderna, Inc

Zitieren

APA

Chalkias, S., Pragalos, A., Akinsola, A., Berman, G., Ampajwala, M., Meyer, J., Schoch, L., Zhou, W., Paila, Y. D., Deng, W., Feng, J., de Windt, E., Edwards, D., Miller, J., & Das, R. (2025). Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA Vaccine. The Journal of Infectious Diseases, 231(4), e754-e763. https://doi.org/10.1093/infdis/jiaf022

Vancouver

Chalkias S, Pragalos A, Akinsola A, Berman G, Ampajwala M, Meyer J, et al. Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA Vaccine. The Journal of Infectious Diseases. 2025;231(4):e754-e763. doi:10.1093/infdis/jiaf022

BibTeX
@article{Chalkias2025,
  author = {Chalkias, Spyros and Pragalos, Antionette and Akinsola, Adebayo and Berman, Gary and Ampajwala, Madhavi and Meyer, Jay and Schoch, Lorraine and Zhou, Wen and Paila, Yamuna D and Deng, Weiping and Feng, Jing and de Windt, Elizabeth and Edwards, Darin and Miller, Jacqueline and Das, Rituparna},
  title = {Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA Vaccine},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  volume = {231},
  number = {4},
  pages = {e754--e763},
  doi = {10.1093/infdis/jiaf022}
}
Kostenlos starten →